# Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

> **NCT03202563** · PHASE4 · COMPLETED · sponsor: **LG Chem** · enrollment: 71 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Gemigliptin 50mg
- **DRUG:** Dapagliflozin 10mg
- **PROCEDURE:** Diet/exercise questionnaire
- **DEVICE:** Continuous Glucose Monitoring System(CGMS)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03202563
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-09
- **Primary completion:** 2018-07-13
- **Final completion:** 2018-12-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202563, "Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03202563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*